2.46 -0.12 (-4.71%)
IMMU
Stock Details
Last Trade:2.46 Change:-0.12 (-4.71%) Prev Close:2.58 Open: 2.55 Days Range:2.42 – 2.55 52 Week Range: 0.84 - 2.85 Volume:230902 P/E: N/AEPS:-0.08
View AllRecent Alerts 07/04/09
Recent Alert on 06/17/09 at 8:39am
Immunomedics (IMMU) Announces Improved Efficacy of Veltuzumab and Pretargeted Anti-CD20 Combo in Lymphoma Model
Immunomedics (IMMU) Announces Improved Efficacy of Veltuzumab and Pretargeted Anti-CD20 Combo in Lymphoma Model
Immunomedics, Inc. (Nasdaq: IMMU) today announced that naked veltuzumab enhances the therapeutic response to a veltuzumab-based pretargeted radioimmunotherapy in a human non-Hodgkin's lymphoma model. RAIT utilizes an antibody to deliver targeted... Read More
Recent Alert on 06/16/09 at 9:47am
Immunomedics (IMMU) Reports New Antibody for Pretargeted Imaging and Therapy of Colorectal Cancer
Immunomedics (IMMU) Reports New Antibody for Pretargeted Imaging and Therapy of Colorectal Cancer
Recent Alert on 06/15/09 at 9:30am
Immunomedics (IMMU) Reports Updated Phase II Results With Radiolabeled Epratuzumab in Non-Hodgkin's Lymphoma
Immunomedics (IMMU) Reports Updated Phase II Results With Radiolabeled Epratuzumab in Non-Hodgkin's Lymphoma
Recent Alert on 06/15/09 at 9:30am
Immunomedics (IMMU) Reports Updated Phase II Results With Radiolabeled Epratuzumab in Non-Hodgkin's Lymphoma
Immunomedics (IMMU) Reports Updated Phase II Results With Radiolabeled Epratuzumab in Non-Hodgkin's Lymphoma
Recent Alert on 06/05/09 at 12:00pm
Immunomedics (IMMU) Announces Positive Results of Low-Dose Veltuzumab
Immunomedics (IMMU) Announces Positive Results of Low-Dose Veltuzumab
View AllRecent Press Releases
No Recent Press Releases Available
View AllRecent SEC Filings
No Recent SEC Filings Available
View AllRecent Blog Posts
No Recent Blog Posts Available